AC
GRTX

Aristides Capital’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Aristides Capital’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,000
Closed -$92K – 308
2021
Q4 		$92K Buy
+20,000
New +$66.1K 0.04% 245

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Aristides Capital's GRTX Position: Q1 2022 in Review

Aristides Capital sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q1 2022, closing a stake of 20,000 shares — an estimated $92K sold.

Aristides Capital first reported a position in GRTX in Q4 2021 and held it in 1 quarter. The position peaked at $92K in Q4 2021. 47 funds tracked by Wall St. Rank hold GRTX as of Q1 2022.

  • Aristides Capital reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Aristides Capital sold 20,000 Galera Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $92K.
  • Aristides Capital first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Aristides Capital's Galera Therapeutics, Inc. Common Stock position peaked at $92K in Q4 2021.
  • 47 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Aristides Capital's 13F filing for Q1 2022, filed 16 May 2022.